A set of recommendations developed by an international panel of experts could have an impact on the care of patients with systemic sclerosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Pope, J. E., Ouimet, J. & Krizova, A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum. 55, 138–145 (2006).
Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. doi: 10.1136/ard.2008.096677 (2009).
Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841–1847 (2001).
Pope, J. et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.:CD000953. doi: 10.1002/14651858.CD000953 (2000).
Malefant, D., Catton, M. & Pope, J. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford) (in press).
Johnson, S., Feldman, B., Pope, J. & Tomlinson, G. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J. Rheumatol. 36, 323–329 (2009).
Pope, J. E. Musculoskeletal involvement in scleroderma. Rheum. Dis. Clin. North Am. 29, 391–408 (2003).
Hachulla, E. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 52, 3792–3800 (2005).
Pope, J. E. et al. The prevalence of pulmonary arterial hypertension in a large Canadian multi-centre cohort of systemic sclerosis subjects. (PHASE study) [abstract]. J. Rheumatol. 31, 1440 (2004).
Villela, R. et al. Assessment of unmet needs in the design of randomized controlled trials and the lack of generalizability for scleroderma treatment. Arthritis Rheum. 59, 706–713 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Pope, J. New evidence-based guidelines for treating SSc. Nat Rev Rheumatol 5, 300–302 (2009). https://doi.org/10.1038/nrrheum.2009.98
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.98
This article is cited by
-
Targeted therapy for systemic sclerosis: how close are we?
Nature Reviews Rheumatology (2010)